Accelerate your oncology, immunology, and other disease area programs with the largest and most comprehensively characterized FFPE inventory—backed by industry-leading acceptance rates, rigorous 12-point quality checks, triple pathology review, and AI-powered tumor quantification.
Discovery Life Sciences takes a Science at Your Service™ approach to provide scientists worldwide with a diverse range of highly characterized (hyper annotated®) human FFPE biospecimens to accelerate all your programs.
3x pathologist-reviewed FFPE tissue with 40x digital H&E scans available from over 30,000 cases.
Discovery’s quality FFPE tissue matched with dissociated tumor cells with cell count and HLA-typing
NGS-characterized FFPE tissue. >40,000+ detections of 500+ specific genes across 19 oncology indications and 900+ unique patients.
Mirrored pairs of consented flash frozen tissue and FFPE. More than 175mg of flash frozen tissue & full FFPE blocks.
1,200+ detections of 54 clinically relevant genes across 30 oncology indications and 200+ unique patients.
Quality Discovery Life Sciences FFPE with matched plasma (Streck and K2EDTA available) and buffy coat.
Discovery has deployed PathAI’s AISight® workflow solutions in our pathology workflow, enabling a new level of precision in tumor content quantification. AI-annotation is able to calculate tumor percent at a decimal-point level of precision, surpassing the traditional qualitative assessments of pathologists and empowering faster turnaround times for large-scale research projects.
ArtifactDetect automatically identifies potential histology and scanning QC issues.
TumorDetect identifies and quantifies cancer area, cancer stroma, and necrosis.
AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland. ArtifactDetect and TumorDetect are research use only products available on AISight® Image Management System, not for use in diagnostic procedures.
Discovery’s proprietary dual nucleic acid extraction enables reliable, reproducible low-input RNA-Seq
Optimized Methods For Sequencing RNA From FFPE Samples White Papers
ASHG 2019 Presentation Webinars & Videos
AACR 2023 - Characterization of a Novel Immunohistochemistry (IHC) Assay for CEACAM5 Using a Commercial Antibody Abstracts & Posters
While our biospecimens are highly characterized, we also provide streamlined multi-omic analyses to further characterize biospecimens from our inventory or from your studies via our global CLIA / CAP service laboratories.*
*Not all service laboratories have CLIA certification or CAP accreditation. Inquire to learn more.
Expertise across different molecular pathology platforms in CLIA-certified, CAP-accredited, and GCLP-compliant laboratories.
